His scientific interests lie mostly in Immunology, Pathology, Internal medicine, Langerhans cell histiocytosis and Histiocytosis. His work deals with themes such as Mycobacterium bovis and Tuberculosis, which intersect with Immunology. His research in Pathology intersects with topics in Mutation, Hematology and Immunophenotyping.
His studies in Internal medicine integrate themes in fields like Gastroenterology, Surgery and Oncology. His biological study spans a wide range of topics, including Targeted therapy, Colorectal cancer, KRAS and Hazard ratio. The Histiocytosis study combines topics in areas such as Malignant histiocytosis, Biopsy and Nose.
Jean-François Emile spends much of his time researching Internal medicine, Pathology, Oncology, Cancer research and Histiocytosis. The concepts of his Internal medicine study are interwoven with issues in Gastroenterology and Surgery. In most of his Pathology studies, his work intersects topics such as Langerhans cell.
The study incorporates disciplines such as KRAS, Cetuximab, FOLFOX and Prospective cohort study in addition to Oncology. His Cancer research study integrates concerns from other disciplines, such as Mutation and Immunology. His Histiocytosis research integrates issues from Histiocyte, Dermatology and Biopsy.
His primary areas of study are Internal medicine, Histiocytosis, Oncology, Erdheim–Chester disease and Cancer research. Internal medicine is often connected to Gastroenterology in his work. Histiocytosis is the subject of his research, which falls under Pathology.
In his study, Rare disease is inextricably linked to Langerhans cell, which falls within the broad field of Pathology. His Oncology study combines topics in areas such as Pembrolizumab, Stage III Colon Cancer, Chemotherapy, Adverse effect and Adenocarcinoma. His work in Colorectal cancer covers topics such as Immune system which are related to areas like Cytokine.
Jean-François Emile mainly focuses on Cancer research, Internal medicine, Colorectal cancer, Histiocytosis and Gastroenterology. His Internal medicine research is multidisciplinary, incorporating perspectives in Microbiome and Oncology. As a part of the same scientific study, Jean-François Emile usually deals with the Colorectal cancer, concentrating on Immune system and frequently concerns with Stromal cell, Stroma, Fibrosis and Inflammation.
His Histiocytosis study is concerned with Pathology in general. His Pathology research is multidisciplinary, incorporating elements of Langerhans cell and Concomitant. He has included themes like KRAS and Pathological in his Gastroenterology study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Astrid Lièvre;Jean-Baptiste Bachet;Delphine Le Corre;Valérie Boige.
Cancer Research (2006)
KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
Astrid Lièvre;Jean-Baptiste Bachet;Valérie Boige;Anne Cayre.
Journal of Clinical Oncology (2008)
INTERFERON-GAMMA-RECEPTOR DEFICIENCY IN AN INFANT WITH FATAL BACILLE CALMETTE-GUERIN INFECTION
Emmanuelle Jouanguy;Frédéric Altare;Salma Lamhamedi;Patrick Revy.
The New England Journal of Medicine (1996)
Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency
Frédéric Altare;Anne Durandy;David Lammas;Jean-François Emile.
Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO
Jean Yves Blay;Sylvie Bonvalot;Paolo Casali;Haesun Choi.
Annals of Oncology (2005)
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages.
Jean-François Emile;Oussama Abla;Sylvie Fraitag;Annacarin Horne.
Foamy Macrophages from Tuberculous Patients' Granulomas Constitute a Nutrient-Rich Reservoir for M. tuberculosis Persistence
Pascale Peyron;Julien Vaubourgeix;Julien Vaubourgeix;Yannick Poquet;Yannick Poquet;Florence Levillain;Florence Levillain.
PLOS Pathogens (2008)
Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).
Nicolas Mounier;Josette Briere;Christian Gisselbrecht;Jean-Francois Emile.
A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection
Emmanuelle Jouanguy;Salma Lamhamedi-Cherradi;David Lammas;Susan E. Dorman.
Nature Genetics (1999)
High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses
Julien Haroche;Frédéric Charlotte;Laurent Arnaud;Andreas von Deimling.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: